Data from clinical studies from medications in development from Allergan will be presented during the American Society for Microbiology (ASM) Microbe event that will be taking place this week in Boston.
A total of 14 presentations will be featuring the company’s portfolio of anti-infective products. A majority of these will be focused on the company’s ceftazidime and avibactam medication, AVYCAZ. The company states that this medicine features antimicrobial properties to treat gram-negative pathogens.
"With the threat of difficult-to-treat infections on the rise, Allergan continues to develop new treatments and evolve existing therapies to address the challenges of these serious pathogens," Chief Research and Development Officer of Allergen David Nicholson said. "These data inform the ongoing research and development of our entire anti-infective portfolio and further support our mission to provide physicians with the right tools to fight serious infections caused by gram-negative and gram-positive pathogens, for which limited treatment options are currently available."
There will also be information from the International Network for Optimal Resistance Monitoring (INFORM) program.
Presentations will also feature TEFLARO and DALLIANCE , which treats bacterial skin infections and gram-positive pathogens, respectively.
This meeting is the first to combine the general meeting of the ASM and the annual meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).